MLV

MLV reiterates its Buy rating and $4 target price on Zalicus (NASDAQ: ZLCS) as a lawsuit settlement involving Exalgo allows company to market generic version six months in advance of plans. MLV says, "In the settlement, Watson Pharmaceuticals will be permitted to launch certain dosage forms of a...

MLV maintains its Buy, $15 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) as the company undertakes strategic restructuring. MLV says, "ALNY announced a restructuring plan that will redefine its clinical pipeline focus, and reduce its cash operating expenses by $20M in 2012. Specifically...

MLV initiates coverage of Avanir Pharmaceuticals (NASDAQ: AVNR) with a Buy rating and a $6 price target as it views the company as a pure-play, execution-focused CNS. MLV says, "NUEDEXTA® has given AVNR ‘foot-in-the-door' status amongst commercial CNS players, in our opinion. In 4Q:11,...

According to MLV, Inhibitex (NASDAQ: INHX) price target is raised to $26. MLV said that prior to start of the first major healthcare conference in San Francisco, Inhibitex announced that it signed a definitive agreement with Bristol-Myers Squibb Company (BMY, Not Covered) to be acquired for $26.00...

MLV & Co initiates coverage on Zalicus (NASDAQ: ZLCS) with a Buy rating and a $4 target price to reflect the company's clinical development for 2012. MLV & Co says, "looking ahead to the company's 2012 clinical developments for their drug candidates for pain and inflammation. The company...

MLV is out with a research report on Cerus Corp. (NASDAQ: CERS) and it is reiterating its Buy rating and raising its price target to $5. In a note to clients, MLV writes, "Cerus announced that it has signed a new two-year supply agreement with the French National Blood Service (EFS) for plasma and...

MLV is out with a research report on Inhibitex, Inc. (NASDAQ: INHX) and it is raising its price target to $15, and it has a Buy rating on shares. In a note to clients, MLV writes, "This morning before the markets opened, INHX announced top-line data studying the safety, efficacy, and tolerability...

MLV is out with its report today on Double Eagle Petroleum (NASDAQ: DBLE), maintaining Buy. In its report, MLV writes, "We believe DBLE is being lumped into a group of cash-strapped companies and being punished by a gas bear mentality, when in fact the company has a strong hedge position into 2013...

According to McNicoll Lewis Vlak, Sunesis Pharmaceuticals (NASDAQ: SNSS) coverage is initiated with a Buy rating. MLV said that Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company developing novel anti-cancer therapies. “Although vosaroxin is Sunesis' only significant asset at this time,...

MLV is out with a research report on Agenus Inc. (NASDAQ: AGEN) and is initiating coverage with a Buy rating and a $2.50 price target on shares. In a note to clients, MLV writes, "We consider Agenus' big Pharma partnerships for the development of its QS-21 adjuvant for multiple vaccines as...

MLV is out with its report today on Aastrom Biosciences (NASDAQ: ASTM), raising its PT to $7.50 from $5.50. In its report, MLV writes, "We have revised our model and project that Aastrom could become profitable in 2015 following the launch of ixmyelocel-T (assuming REVIVE produces positive results...

MLV is out with its report today on ArQule (NASDAQ: ARQL), maintaining Buy. in its report, MLV writes, "We have revised our model and now project that ArQule could become sustainably profitable in 2015 based on the launch of tivantinib for NSCLC and HCC (if results of the ongoing trials are...

MLV reiterated its Buy rating on Novavax (NASDAQ: NVAX). At the same time, the rating agency reduced its price target on the company's stock from $11 to $9.50. On Thursday, NVAX closed the day at $1.33.

MLV is out with its report today on Genomic Health (NASDAQ: GHDX), maintaining Buy. In its report, MLV writes, "Genomic Health ended 2Q:10 with $61 million in cash, cash equivalents, and investments; a decrease of $2.6 million from 1Q:11. The company has been profitable in four of the last five...

MLV provided color on Affymax (NASDAQ: AFFY). In a research report published today, the rating agency commented on the company's new drug peginesatide. In the report, MLV states, “This morning, Affymax and its partner Takeda (TSE: 4502; Not Covered) announced the NDA acceptance by the FDA for...